Department of Gastroenterology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou 450003, China.
Hepatobiliary Pancreatic Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China.
Gene. 2025 Jan 20;934:149035. doi: 10.1016/j.gene.2024.149035. Epub 2024 Oct 24.
Pancreatic adenocarcinoma (PAAD) is a highly aggressive cancer with a poor prognosis, highlighting an urgent requirement for effective biomarkers for its early diagnosis and prognosis prediction. CAPN2, a calcium-dependent protease, has been implicated in various cancers, but its role in PAAD remains unclear.
In this study, we utilized multiple bioinformatics methods, including differential expression, survival, correlation, and enrichment analyses, to investigate the prognostic value of CAPN2 in PAAD using data from the TCGA and GEO databases. Additionally, the correlation between CAPN2 expression and the tumor microenvironment (TME), immunotherapy potential, and drug sensitivity was also explored.
CAPN2 was upregulated in PAAD tissues and was correlated with higher tumor grade. And high expression of CAPN2 was significantly associated with reduced overall survival, establishing it as an independent prognostic biomarker for PAAD. Enrichment analysis implicated that CAPN2 was involved in multiple biological processes and pathways associated with tumor immunity. Furthermore, CAPN2 expression had a negative correlation with immune cell infiltration and a positive association with tumor mutational burden, which may have potential implications for immunotherapy strategies.
CAPN2 is a promising biomarker for PAAD prognosis and a potential therapeutic target. Its association with the TME and immunotherapy response highlights its importance in PAAD progression and patient outcomes, warranting further investigation into its role and potential clinical applications.
胰腺导管腺癌(PAAD)是一种侵袭性强、预后差的癌症,迫切需要有效的生物标志物来进行早期诊断和预后预测。钙蛋白酶 2(CAPN2)是一种钙依赖性蛋白酶,与多种癌症有关,但它在 PAAD 中的作用尚不清楚。
本研究利用 TCGA 和 GEO 数据库中的差异表达、生存、相关性和富集分析等多种生物信息学方法,研究 CAPN2 在 PAAD 中的预后价值。此外,还探讨了 CAPN2 表达与肿瘤微环境(TME)、免疫治疗潜力和药物敏感性的相关性。
CAPN2 在 PAAD 组织中上调,与肿瘤分级较高相关。CAPN2 高表达与总生存期缩短显著相关,是 PAAD 的独立预后生物标志物。富集分析表明,CAPN2 参与了多个与肿瘤免疫相关的生物学过程和途径。此外,CAPN2 表达与免疫细胞浸润呈负相关,与肿瘤突变负荷呈正相关,这可能对免疫治疗策略具有潜在意义。
CAPN2 是 PAAD 预后的一个有前途的生物标志物,也是一个潜在的治疗靶点。它与 TME 和免疫治疗反应的关联突显了其在 PAAD 进展和患者结局中的重要性,值得进一步研究其作用和潜在的临床应用。